Clinical Trial Update: Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating MabCampath for relapsed T-cell acute lymphoblastic leukemia or T-lymphoblastic lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-lymphoblastic Lymphoma

Drugs mentioned

• MabCampath (alemtuzumab)

Snippet

Sponsor: Goethe University | Conditions: Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic | Phase 2 | Status: COMPLETED